| Quantity | 5 mg, 10 mg, 25 mg, 50 mg | 500 µ, g, 1 mg | 250 µ, L, 500 µ, L, 1 mL | 1 mg, 5 mg, 10 mg | 500 µ, g, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |
| Description | Cyclo(Pro-Thr) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research Cyclo(Pro-Thr) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development[1]... Read More | α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC50 of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 µM[1][2] | The 1 kb DNA Marker is provided in a solution of 1× DNA Loading Buffer, which can be directly used for nucleic acid electrophoresis analysis. The 250 µL is defined as the base specification. All larger sizes correspond to incremental volumes of this base | pTH (39-84) (human) is a parathyroid hormone (PTH) C-terminal fragment. pTH (39-84) (human) stimulates osteoclast formation[1] | WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the WP9QY, TNF-a Antagonist, TNF-a Antagonist is a biological active peptide. (This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I. It prevents interactions of TNF with its receptor. This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.)... Read More |